Technology Bundle ID
TAB-2437

Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling

Applications
Linked ID
E-073-2012-0
Lead Inventors
Kenneth Jacobson (NIDDK)
Development Status
  • Early-stage
  • In vitro data available
Disease Areas
ICs
This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3 adenosine receptors.

Small molecule drugs, A3AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, and dry eye disease, and other conditions.
Commercial Applications
  • Tools to study prevalence of this receptor on neutrophils, a predictor of response to agonist drugs.
Competitive Advantages
  • Avoids the use of radioisotopes in this part of the R&D process.

Request More Info

Licensing Contact: